Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
Seronegative spondyloarthropathies and the eye
Amro Ali
, C. Michael Samson
Research output
:
Contribution to journal
›
Review article
›
peer-review
23
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Seronegative spondyloarthropathies and the eye'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Seronegative Spondyloarthropathy
100%
Ocular Inflammation
50%
Uveitis
50%
Spondyloarthropathy
50%
Steroid Treatment
50%
Inflammation
25%
Genetic Factors
25%
Environmental Factors
25%
Strong Correlation
25%
Popular
25%
Methotrexate
25%
Infliximab
25%
Anterior Uveitis
25%
Best Response
25%
Immunomodulator
25%
Etanercept
25%
Chronic Uveitis
25%
Immunosuppressive Agents
25%
Causes of Blindness
25%
Ocular Surgery
25%
HLA-B27
25%
Ocular Manifestations
25%
Tumour Necrosis Factor Inhibitor (TNFi)
25%
Eye Diseases
25%
Vision Rehabilitation
25%
Medicine and Dentistry
Spondyloarthropathy
100%
Uveitis
50%
Eye Disease
33%
Eye Inflammation
33%
Steroid Treatment
33%
Biological Product
16%
Immunosuppressive Drug
16%
Methotrexate
16%
Environmental Factor
16%
Infliximab
16%
Immunomodulating Agent
16%
Etanercept
16%
Eye Surgery
16%
TNF Inhibitor
16%
Iridocyclitis
16%
Vision Rehabilitation
16%
HLA-B27
16%
Diseases
16%
Nursing and Health Professions
Spondyloarthropathy
100%
Uveitis
50%
Eye Disease
33%
Eye Inflammation
33%
Inflammation
16%
Biological Product
16%
Immunosuppressive Agent
16%
Methotrexate
16%
Infliximab
16%
Etanercept
16%
Tumor Necrosis Factor Inhibitor
16%
Vision Rehabilitation
16%
Iridocyclitis
16%
Immunomodulating Agent
16%
Eye Surgery
16%
Diseases
16%
Pharmacology, Toxicology and Pharmaceutical Science
Spondyloarthropathy
100%
Uveitis
50%
Eye Inflammation
33%
Eye Disease
33%
Steroid Treatment
33%
Immunosuppressive Agent
16%
Inflammation
16%
Biological Product
16%
Methotrexate
16%
Infliximab
16%
Immunomodulating Agent
16%
Iridocyclitis
16%
Etanercept
16%
Tumor Necrosis Factor Inhibitor
16%
Diseases
16%